Evidence map›Paper›PMID 38672604›Full record

ArticleCancers2024

What Have We Learned about the Prevention of NMSC from Albino Patients from Malawi? Secondary Prevention Maintained over Time.

Alejandra Tomás-Velázquez, Ester Moreno-Artero, Javier Romero, Pilar Escalonilla, Isabel Medina, Gisela Hebe Petiti, Pedro Redondo

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alejandra Tomás-VelázquezDermatology Department, Clínica Universidad de Navarra, 28027 Madrid, Spain.ORCID 0000-0002-9216-4461
Ester Moreno-ArteroDermatology Department, Hospital Universitario Galdakao, 48960 Galdakao, Spain.
Javier RomeroRomero y Medina Dermatology Clinic, 29640 Fuengirola, Spain.
Pilar EscalonillaDermatology Department, Complejo Asistencial de Ávila, 05071 Ávila, Spain.
Isabel MedinaRomero y Medina Dermatology Clinic, 29640 Fuengirola, Spain.
Gisela Hebe PetitiDermatology Department, Consorci Sanitari Integral, Hospital Dos de Mayo, 08025 Barcelona, Spain.
Pedro RedondoDermatology Department, Clínica Universidad de Navarra, 28027 Madrid, Spain.ORCID 0000-0001-7899-2511

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have conducted cooperative campaigns focusing on albino patients in a rural area of Malawi. What have we learned?

methodsThree surgical campaigns were performed in Nkhotakota district (2019-2023). Albino clinical and tumor characteristics were collected.

resultsBetween 22 and 75 albinos were evaluated in each campaign (mean age < 28 years old). Most patients did not use sunscreen in a way that provided optimal photoprotection. Regarding tumors, the proportion of basal and squamous cell carcinomas ranged from 1:1 to almost 2:1. Of 156 albino patients, 34 attended more than once. However, of the 19 patients with 30 tumors operated on in 2021, only seven were assessed the following year (12 were lost to follow-up). At least 14 albinos with locally advanced tumors were evaluated.

conclusionsDistributing photoprotective clothing could be more efficient or perhaps an earlier measure of sunscreen in rural Africa as it does not require permanent repositioning. Very-high-risk patients (previous interventions with positive margins or high-risk tumors, intense actinic damage, and new tumors constantly appearing, especially those presenting SCCs) require close follow-up and treatment and represent our main target. Secondary prevention with Malawian collaboration and the use of teledermatology is essential for patient tracking, as they are able to offer curative treatments.

Indexed as

AfricaalbinismdiagnosisMalawipreventionskin cancersquamous cell carcinomasurgerytreatment

Identifiers

PMID38672604
PMCPMC11048476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.